Table 1.
Baseline clinical characteristics of AGC patients.
| Total (n=106) | NLR≤3.11 | NLR>3.11 | P | PLR≤243.33 | PLR>243.33 | P | MLR≤0.20 | MLR>0.20 | P | dNLR≤2.09 | dNLR>2.09 | P | SII≤1140.91 | SII>1140.91 | P | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | (n=61) | (n=45) | (n=84) | (n=22) | (n=22) | (n=84) | (n=60) | (n=46) | (n=85) | (n=21) | |||||||
| Age (years) | |||||||||||||||||
| ≤65 | 77 (72.6) | 43 | 34 | 0.563 | 60 | 17 | 0.584 | 15 | 62 | 0.598 | 43 | 34 | 0.797 | 60 | 17 | 0.340 | |
| >65 | 29 (27.4) | 18 | 11 | 24 | 5 | 7 | 22 | 17 | 12 | 25 | 4 | ||||||
| Gender | |||||||||||||||||
| Male | 72 (67.9) | 43 | 29 | 0.510 | 57 | 15 | 0.977 | 15 | 57 | 0.977 | 43 | 29 | 0.346 | 59 | 13 | 0.509 | |
| Female | 34 (32.1) | 18 | 16 | 27 | 7 | 7 | 27 | 17 | 17 | 26 | 8 | ||||||
| Differentiation | |||||||||||||||||
| Poor | 61 (60.4) | 32 | 29 | 0.079 | 49 | 12 | 0.785 | 8 | 53 | 0.009 | 33 | 28 | 0.180 | 48 | 13 | 0.427 | |
| Moderate or Well | 40 (39.6) | 28 | 12 | 33 | 7 | 14 | 26 | 27 | 13 | 34 | 6 | ||||||
| Location | |||||||||||||||||
| Upper | 35 (34.3) | 20 | 15 | 0.084 | 27 | 8 | 0.586 | 10 | 25 | 0.582 | 20 | 15 | 0.318 | 28 | 7 | 0.772 | |
| Middle | 21 (20.6) | 9 | 12 | 17 | 4 | 3 | 18 | 9 | 12 | 16 | 5 | ||||||
| Low | 34 (33.3) | 25 | 9 | 30 | 4 | 6 | 28 | 23 | 11 | 29 | 5 | ||||||
| Others | 12 (11.8) | 5 | 7 | 9 | 3 | 3 | 9 | 6 | 6 | 9 | 3 | ||||||
| Metastatic site | |||||||||||||||||
| Peritoneal metastasis | |||||||||||||||||
| Negative | 77 (72.6) | 49 | 28 | 0.039 | 62 | 15 | 0.598 | 18 | 59 | 0.278 | 50 | 27 | 0.005 | 65 | 12 | 0.075 | |
| Positive | 29 (27.4) | 12 | 17 | 22 | 7 | 4 | 25 | 10 | 19 | 20 | 9 | ||||||
| Liver metastasis | |||||||||||||||||
| Negative | 64 (60.4) | 36 | 28 | 0.739 | 51 | 13 | 0.890 | 14 | 50 | 0.726 | 35 | 29 | 0.623 | 49 | 15 | 0.248 | |
| Positive | 42 (39.6) | 25 | 17 | 33 | 9 | 8 | 34 | 25 | 17 | 36 | 6 | ||||||
| Lymph node metastasis | |||||||||||||||||
| Negative | 30 (28.3) | 18 | 12 | 0.748 | 23 | 7 | 0.681 | 6 | 24 | 0.904 | 18 | 12 | 0.658 | 26 | 4 | 0.293 | |
| Positive | 76 (71.7) | 43 | 33 | 61 | 15 | 16 | 60 | 42 | 34 | 59 | 17 | ||||||
| Lung metastasis | |||||||||||||||||
| Negative | 90 (84.9) | 53 | 37 | 0.507 | 70 | 20 | 0.515 | 19 | 71 | >0.999 | 52 | 38 | 0.563 | 73 | 17 | 0.517 | |
| Positive | 16 (15.1) | 8 | 8 | 14 | 2 | 3 | 13 | 8 | 8 | 12 | 4 | ||||||
| Number of metastatic sites | |||||||||||||||||
| ≤2 | 77 (72.6) | 49 | 28 | 0.039 | 63 | 14 | 0.287 | 20 | 57 | 0.031 | 50 | 27 | 0.005 | 66 | 11 | 0.020 | |
| ≥3 | 29 (27.4) | 12 | 17 | 21 | 8 | 2 | 27 | 10 | 19 | 19 | 10 | ||||||
| ECOG PS | |||||||||||||||||
| 0-1 | 99 (93.4) | 59 | 40 | 0.132 | 77 | 22 | 0.340 | 21 | 78 | >0.999 | 58 | 41 | 0.235 | 81 | 18 | 0.138 | |
| ≥2 | 7 (6.6) | 2 | 5 | 7 | 0 | 1 | 6 | 2 | 5 | 4 | 3 | ||||||
| First line chemotherapy | |||||||||||||||||
| Fluorouracil +Platinum | 65 (61.3) | 40 | 25 | 0.426 | 50 | 15 | 0.695 | 14 | 51 | 0.571 | 41 | 24 | 0.146 | 51 | 14 | 0.773 | |
| Fluorouracil +Taxanes | 14 (13.2) | 6 | 8 | 11 | 3 | 4 | 10 | 5 | 9 | 11 | 3 | ||||||
| Others | 27 (25.5) | 15 | 12 | 23 | 4 | 4 | 23 | 14 | 13 | 23 | 4 | ||||||
| Response after chemotherapy | |||||||||||||||||
| CR+PR | 24 (22.6) | 14 | 10 | 0.097 | 19 | 5 | >0.999 | 4 | 20 | 0.155 | 16 | 8 | 0.055 | 21 | 3 | 0.206 | |
| SD | 53 (50.0) | 35 | 18 | 42 | 11 | 15 | 38 | 33 | 20 | 44 | 9 | ||||||
| PD | 29 (27.4) | 12 | 17 | 23 | 6 | 3 | 26 | 11 | 18 | 20 | 9 | ||||||
| Alcohol Consumption | |||||||||||||||||
| Abstinence or low risk | 94 (88.7) | 54 | 40 | 0.953 | 73 | 21 | 0.453 | 20 | 74 | >0.999 | 53 | 41 | 0.898 | 76 | 18 | 0.701 | |
| Hazardous or harmful | 12 (11.3) | 7 | 5 | 11 | 1 | 2 | 10 | 7 | 5 | 9 | 3 | ||||||
| Drugs | |||||||||||||||||
| Camrelizumab | 54 (50.9) | 31 | 23 | 0.137 | 47 | 7 | 0.086 | 13 | 41 | 0.602 | 31 | 23 | 0.717 | 46 | 8 | 0.216 | |
| Sintilimab | 37 (34.9) | 22 | 15 | 27 | 10 | 7 | 30 | 21 | 16 | 28 | 9 | ||||||
| Toripalimab | 5 (4.7) | 5 | 0 | 4 | 1 | 1 | 4 | 4 | 1 | 5 | 0 | ||||||
| Pembrolizumab | 7 (6.6) | 2 | 5 | 5 | 2 | 0 | 7 | 3 | 4 | 4 | 3 | ||||||
| Nivolumab | 3 (2.8) | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | ||||||
| LDH | |||||||||||||||||
| ≤250 | 75 (71.4) | 45 | 30 | 0.350 | 58 | 17 | 0.495 | 13 | 62 | 0.280 | 45 | 30 | 0.214 | 62 | 13 | 0.280 | |
| >250 | 30 (28.6) | 15 | 15 | 25 | 5 | 8 | 22 | 14 | 16 | 22 | 8 | ||||||
| CEA | |||||||||||||||||
| ≤5 | 43 (44.8) | 20 | 23 | 0.034 | 32 | 11 | 0.200 | 6 | 37 | 0.135 | 21 | 22 | 0.089 | 34 | 9 | 0.313 | |
| >5 | 53 (55.2) | 36 | 17 | 45 | 8 | 14 | 39 | 35 | 18 | 46 | 7 | ||||||
| CA199 | |||||||||||||||||
| ≤37 | 58 (60.4) | 37 | 21 | 0.180 | 48 | 10 | 0.640 | 14 | 44 | 0.508 | 37 | 21 | 0.180 | 51 | 7 | 0.074 | |
| >37 | 38 (39.6) | 19 | 19 | 30 | 8 | 7 | 31 | 19 | 19 | 28 | 10 | ||||||
| CA724 | |||||||||||||||||
| ≤8.2 | 60 (75.9) | 37 | 23 | 0.271 | 49 | 11 | 0.336 | 14 | 46 | 0.749 | 38 | 22 | 0.102 | 51 | 9 | 0.176 | |
| >8.2 | 19 (24.1) | 9 | 10 | 13 | 6 | 3 | 16 | 8 | 11 | 13 | 6 | ||||||
| Molecular classification | |||||||||||||||||
| HER negative | 72 (67.9) | 41 | 31 | 0.315 | 56 | 16 | 0.516 | 14 | 58 | 0.783 | 41 | 31 | >0.999 | 55 | 17 | 0.086 | |
| HER positive | 7 (6.6) | 6 | 1 | 7 | 0 | 2 | 5 | 4 | 3 | 7 | 0 | ||||||
| Unknown | 27 (25.5) | 14 | 13 | 21 | 6 | 6 | 21 | 15 | 12 | 23 | 14 | ||||||